Phase II trial of Sorafenib and Capecitabine in Advanced Renal Cell Carcinoma (RCC)
Phase 2
Completed
- Conditions
- kidney cancerrenal cell carcinoma10038364
- Registration Number
- NL-OMON32358
- Lead Sponsor
- Vrije Universiteit Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 53
Inclusion Criteria
Advanced renal cell carcinoma (metastatic RCC)
Exclusion Criteria
Other types of malignancies
History of cardiac disease
Serious clinical infections
Symptomatic brain metastases
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Progression free survival at 12 months</p><br>
- Secondary Outcome Measures
Name Time Method <p>Overall remission<br /><br>Overall survival<br /><br>Safety</p><br>